Goldenseal is a woodland root supplement used for blood sugar, cholesterol, and microbial defense. No controlled human study tests whole goldenseal alone; low-level blood sugar, cholesterol, and diarrhea evidence comes indirectly from purified berberine. Conversely, human studies show whole goldenseal blocks drug-processing liver enzymes and alters oral medication absorption. Alongside commercial lead contamination, it has an unfavorable longevity risk-to-benefit profile compared with purified berberine. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 10–40 U/L (standard reference range) | Safety check: detects hepatocellular injury from isoquinoline alkaloids or adulterants (discontinuation threshold >3× ULN) |
| AST | 10–40 U/L (standard reference range) | Safety check: evaluates hepatobiliary and cellular toxicity alongside ALT (discontinuation threshold >3× ULN) |
| Total Bilirubin | 0.2–1.2 mg/dL (standard reference range) | Safety check: monitors for berberine-mediated albumin displacement or hemolysis |
| FPG | 70–99 mg/dL (3.9–5.5 mmol/L) (standard reference range) | Expected-change marker & safety check: tracks glycemic reduction or loss of metformin efficacy |
| HbA1c | <5.7% (standard reference range) | Expected-change marker: evaluates 8–12 week glycemic trajectory |
| LDL-C | <100 mg/dL (<2.6 mmol/L) (standard reference range) | Expected-change marker: assesses LDLR-mediated cholesterol clearance (drawn as part of a complete fasting lipid panel including TC and TG) |
| Serum Sodium | 135–145 mEq/L (standard reference range) | Safety check: rules out hypernatremia and hyperosmolality in diabetic or dehydrated states |
| Concomitant CYP3A4 / CYP2D6 / P-gp Drug Troughs (e.g., Cyclosporine, Digoxin) | No established universal target; prescribed agent-specific therapeutic window relative to individual baseline | Safety check: detects goldenseal-induced drug accumulation |
Cadence: Baseline before initiation; hepatic transaminases (ALT, AST), total bilirubin, and serum sodium rechecked at 2 and 4 weeks; concomitant narrow-therapeutic-index medication troughs drawn immediately before the next dose at baseline, 7–14 days after starting or stopping, and at 2 and 4 weeks; fasting plasma glucose (FPG), HbA1c, and complete fasting lipid panel re-evaluated at 8–12 weeks.